Pre-launch · We're opening Reserve Meds to a limited first cohort. Join the waitlist ›
Home / Drugs / Alyftrek

Alyftrek, vanzacaftor/tezacaftor/deutivacaftor

Named-patient access overview. Alyftrek is coordinated by Reserve Meds for international patients via physician-led cross-border sourcing.

About Alyftrek

Alyftrek (vanzacaftor/tezacaftor/deutivacaftor) is manufactured by Vertex Pharmaceuticals and indicated for cystic fibrosis in patients aged 6 and older who have at least one F508del mutation or another responsive CFTR mutation (roughly 94 responsive mutations, ~31 additional vs. Trikafta). It is the next-generation oral once-daily CFTR triple combination, approved by the US FDA in December 2024 as successor to Trikafta. Carries a DILI boxed warning. Available to international patients through Named Patient Program or personal-import pathways via Reserve Meds.

How Reserve Meds coordinates Alyftrek

  1. Patient or treating physician submits a named-patient request.
  2. Clinical team verifies appropriateness of Alyftrek for the patient and destination country.
  3. Treating physician issues prescription and clinical justification.
  4. Country-specific NPP / personal-import documentation is prepared.
  5. Alyftrek is sourced from a DSCSA-compliant US specialty wholesaler with full serial traceability.
  6. Shipment is coordinated to the patient's physician or hospital pharmacy (cold-chain where required).

Access by country

Reserve Meds publishes a detailed country deep-dive for Alyftrek in every market we coordinate. Each page below covers the destination-country regulatory pathway (named-patient framework), real costs in local currency and USD, indicative timelines, physician-credential requirements, and cold-chain handling for the route into that country. Tap any country to read the full deep-dive.

Alyftrek in BahrainFull deep-dive on regulatory pathway, costs, timing Alyftrek in EgyptFull deep-dive on regulatory pathway, costs, timing Alyftrek in IndiaFull deep-dive on regulatory pathway, costs, timing Alyftrek in NepalFull deep-dive on regulatory pathway, costs, timing Alyftrek in PakistanFull deep-dive on regulatory pathway, costs, timing Alyftrek in QatarFull deep-dive on regulatory pathway, costs, timing Alyftrek in Saudi ArabiaFull deep-dive on regulatory pathway, costs, timing Alyftrek in Sri LankaFull deep-dive on regulatory pathway, costs, timing Alyftrek in the UAEFull deep-dive on regulatory pathway, costs, timing

Start a request for Alyftrek

Submit a 60-second intake. Our clinical team will reach out as our first cohort opens with case-specific feasibility, timeline, and a formal quote.

Join the Alyftrek waitlist

About Alyftrek

Cystic fibrosis (pulmonary)
Manufacturer: Vertex Pharmaceuticals
Modality: Oral once-daily CFTR triple combination
Generic: vanzacaftor/tezacaftor/deutivacaftor

Why Reserve Meds

DSCSA-compliant US sourcing. Physician-led. On-pathway in every destination. Patient-first intake with a named concierge.

Related

Access pathways
Country guidance
Articles & guides